Compare HUIZ & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUIZ | VRCA |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 32.7M |
| IPO Year | 2020 | 2018 |
| Metric | HUIZ | VRCA |
|---|---|---|
| Price | $3.55 | $8.00 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $2.30 | N/A |
| AVG Volume (30 Days) | 4.0K | ★ 399.9K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $186,519,166.00 | $30,829,000.00 |
| Revenue This Year | $22.67 | $373.65 |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | $14.22 | ★ N/A |
| Revenue Growth | 19.12 | ★ 234.73 |
| 52 Week Low | $1.50 | $3.28 |
| 52 Week High | $4.53 | $9.82 |
| Indicator | HUIZ | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 54.33 | 62.44 |
| Support Level | $3.46 | $7.82 |
| Resistance Level | $3.79 | $9.78 |
| Average True Range (ATR) | 0.18 | 1.18 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 51.98 | 64.93 |
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.